#Victrelis

Sovaldi (sofosbuvir) is a cost-effective treatment option for hepatitis C among the prison population when compared with other options.

Staging liver fibrosis among those with hepatitis C virus and only treating advanced cases is not cost-effective compared with treating all.

The European Commission has approved Bristol-Myers Squibbâ€™s Daklinza (daclatasvir) to treat genotypes 1 through 4 of hepatitis C virus.

With interferon quickly becoming a thing of the past, what kind of side effects still remain in the new hepatitis C regimens?

The National Association of Medicaid Directors has denounced as poor and potentially biased the available evidence and guidelines supporting S...

There is good news for those who are uninsured, or cannot afford treatment.

As hepatitis C treatment undergoes a revolution, the doors are swinging wide open for people coinfected with HIV to be cured of hep C.

A panel of medical experts in California has lambasted Gilead Sciences for its exorbitant pricing its new hepatitis C treatment, Sovaldi (sofo...

Daclatasvir and Sovaldi, given with or without ribavirin, cured between 92 and 100 percent of people with genotypes 1, 2 and 3 of hepatitis C.

“This is a very significant advance.”

A recent liver conference made it more clear than ever that the means to blow hepatitis C off the map is just within reach.

Gilead Sciences has sued Merck to defend its control of sofosbuvir, a late-stage experimental drug for the hepatitis C virus.

Victrelis, when added to interferon and ribavirin, improves cure rates of hepatitis C and does not raise major treatment risks in those coinfe...

The FDA has sped up the development and approval process for promising new hepatitis C therapies from three different companies.

In Preparing for Hep C Triple Therapy you need understanding of treatment side effects and how to deal with them effectively. Learn helpful to...

Do you need information on how to prepare for Hep C Triple Therapy? The Preparation phase is a very important part of treatment. Here are some...